Granted Patent
B2
US 12,679,877 · App. 16/577,947 · Granted Jul 14, 2026
NPRA agonists, compositions, and uses thereof
Inventors:
Gerardo M. Castillo (Bothell, WA); Akiko Nishimoto-Ashfield (Bothell, WA); Elijah M. Bolotin (Bothell, WA)
Assignee:
PharmaIN Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure provides a natriuretic peptide derivative of Formula (I), and to compositions including a natriuretic peptide derivative of Formula (I), (fatty acyl) z -(B) x -(G) y -NP (I), wherein: z is 1, x is an integer from 2 to 4 and y is 3; or z is 0, x is an integer from 0 to 4 and y is an integer from 1 to 3; fatty acyl comprises from 12 to 24 (e.g., 12 to 18) carbons atoms; B is lysine or arginine; G is glycine; NP is a natriuretic peptide; if present, (fatty acyl) z - is covalently linked to the N-terminus of (B) x ; (fatty acyl) z -(B) x — is covalently linked to the N-terminus of (G) y ; and (fatty acyl) z -(B) x -(G) y - is covalently linked to the N-terminus of NP. The natriuretic peptide derivative according to the disclosure, and compositions thereof, are useful in the treatment of diseases such as hypertension, vascular congestion, and heart disease.
Claims (7)
1 . A composition comprising a natriuretic peptide derivative, wherein the natriuretic peptide derivative comprises SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 68, SEQ ID NO: 72, SEQ ID NO: 86, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 113, or SEQ ID NO: 122.
2 . The composition according to claim 1 , wherein the natriuretic peptide derivative is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 56, SEQ ID NO: 52, SEQ ID NO: 113, SEQ ID NO: 68, SEQ ID NO: 122, and SEQ ID NO: 72.
3 . The composition according to claim 1 , wherein the natriuretic peptide derivative is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 56, and SEQ ID NO: 72.
4 . The composition according to claim 1 , wherein the natriuretic peptide derivative is selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 56, SEQ ID NO: 52, SEQ ID NO: 68, SEQ ID NO: 122, and SEQ ID NO: 72.
5 . The composition according to claim 1 , further comprising an excipient.
6 . The composition of claim 1 , wherein the natriuretic peptide derivative is, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 68, SEQ ID NO: 72, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 113, or SEQ ID NO: 122.
7 . A method of increasing blood cGMP in a patient, the method comprising parenterally administering to the patient a composition according to claim 1 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 22, 2019
From: CASTILLO, GERARDO M.; NISHIMOTO-ASHFIELD, AKIKO; BOLOTIN, ELIJAH M.
To: PHARMAIN CORPORATION
Reel/Frame 050794/0308 →
Continuity (3)
Continuation In Part
PCTUS2018023491
· Mar 21, 2018
Provisional Application
62475147
· Mar 22, 2017
References Cited (151)
US 3985722A
· Yoshida et al.
· 1976
[cited by applicant]
US 5439887A
· Hamon et al.
· 1995
[cited by applicant]
US 6660271B2
· Kenten et al.
· 2003
[cited by applicant]
US 7846900B2
· Vesely
· 2010
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8198242B2
· Wendt
· 2012
[cited by examiner]
US 8217149B2
· Irving et al.
· 2012
[cited by applicant]
US 8551937B2
· Wakabayashi
· 2013
[cited by examiner]
US 9745344B2
· Osterkamp et al.
· 2017
[cited by applicant]
US 9759725B2
· Nelson et al.
· 2017
[cited by applicant]
US 20100310561A1
· Canada et al.
· 2010
[cited by applicant]
US 20120220528A1
· Van Antwerp et al.
· 2012
[cited by applicant]
US 20140072557A1
· Kangawa et al.
· 2014
[cited by applicant]
US 20150125457A1
· Wakabayashi et al.
· 2015
[cited by applicant]
US 20150174201A1
· Geimer
· 2015
[cited by applicant]
US 20170196931A1
· Chawla
· 2017
[cited by applicant]
US 20190255183A1
· Sprogøe et al.
· 2019
[cited by applicant]
US 20210079056A1
· Brockschnieder et al.
· 2021
[cited by applicant]
US 20230241164A1
· Tachibana et al.
· 2023
[cited by applicant]
US 20230416328A1
· Tachibana et al.
· 2023
[cited by applicant]
CN 1199097A
· 1998
[cited by applicant]
EP 0037516B1
· 1984
[cited by applicant]
EP 2682128A1
· 2014
[cited by applicant]
EP 2745846A1
· 2014
[cited by applicant]
EP 3189835B1
· 2018
[cited by applicant]
EP 3553079A1
· 2019
[cited by applicant]
JP 2018522022A
· 2018
[cited by applicant]
JP 2020511494A
· 2020
[cited by applicant]
WO 9942472A1
· 1999
[cited by applicant]
WO 0274234A2
· 2002
[cited by applicant]
WO WO2004047871
· 2004
[cited by examiner]
WO 2008154226A1
· 2008
[cited by applicant]
WO 2008156712A1
· 2008
[cited by applicant]
WO 2009067639A2
· 2009
[cited by applicant]
WO 2010129655A2
· 2010
[cited by applicant]
WO 2011066389A1
· 2011
[cited by applicant]
WO 2011075471A2
· 2011
[cited by applicant]
WO 2012088608A1
· 2012
[cited by applicant]
WO 2012118042A1
· 2012
[cited by applicant]
WO 2013027680A1
· 2013
[cited by applicant]
WO 2013151767A1
· 2013
[cited by applicant]
WO 2016077143A1
· 2016
[cited by applicant]
WO 2017082186A1
· 2017
[cited by applicant]
WO 2018175534A1
· 2018
[cited by applicant]
Ostergaard et al. Scientific Reports, 2021, 11:21179.
[cited by examiner]
Office Action mailed Apr. 28. 2022 issued in counterpart Vietnamese Application No., 1-2019-05781 filed Mar. 21, 2018 (3 pages).
[cited by applicant]
European Supplementary Search Report mailed Dec. 16, 2020, issued in corresponding European Application No. 18771099.1, filed Mar. 21, 2018, 7 pages.
[cited by applicant]
International Search Report and Written Opinion mailed May 17, 2018, issued in corresponding International Application No. PCT/US2018/23491, filed Mar. 21, 2018, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability mailed Oct. 3, 2019, issued in corresponding European Application No. PCT/US2018/023491, filed Mar. 21, 2018, 7 pages.
[cited by applicant]
Gupta, D., et al., “Natriuretic Peptides and Cardiometabolic Health”, Circulation Journal, vol. 79, No. 8, 2015, pp. 1647-1655.
[cited by applicant]
Abraham et al., Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury, Am. J. Physiol. Lung Cell. Mol. Physiol. 279: 1137-1145, 2000.
[cited by applicant]
Apodaca, M.C. et al., “Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells,” Journal of Immunotherapy of Cancer, vol. 7; 230; 11 Pages (2019).
[cited by applicant]
Biernacka, A. et al., “TGF-β signaling in fibrosis,” Growth Factors, vol. 29; No. 5; 196-202 (2011).
[cited by applicant]
Black et al., Renal Inflammation and Fibrosis: A Double-edged Sword, Journal of Histochemistry & Cytochemistry 2019, vol. 67(9) 663-681.
[cited by applicant]
Brooks et al., Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009; 119: 1275-85.
[cited by applicant]
Bruno, T.C. et al., “Antigen-presenting intratumoral B cells affect CD4+ TIL phenotypes in non-small cell lung cancer patients,” Cancer Immunol. Res., vol. 5; No. 10; 898-907 (2017).
[cited by applicant]
Castillo et al., Extending residence time and stability of peptides by Protected Graft Copolymer (PGC) excipient: GLP-1 example, Pharm. Res., (2012) 29(1); p. 306-18.
[cited by applicant]
Castillo et al., Protected graft copolymer-formulated fibroblast growth factors mitigate the lethality of partial body irradiation injury, PLoS One, (2017) 12(2); e0171703.
[cited by applicant]
Castillo, G. et al., “Extending residence time and stability of peptides by Protected Graft Copolymer (PGC) excipient: GLP-1 example,” Pharm Res., vol. 29; No. 1; 306-318 (2012).
[cited by applicant]
Castillo, G.M. et al., “Protected graft copolymer-formulated fibroblast growth factors mitigate the lethality of partial body irradiation injury,” PLoS ONE, vol. 12; No. 2; e0171703; 25 pages (2017).
[cited by applicant]
Chopra, S. et al., “Physiology and clinical significance of natriuretic hormones,” Indian Journal of Endocrinology and Metabolism, vol. 17; Issue 1; 83-90 (2013).
[cited by applicant]
Chrisman et al., Seminal Plasma Factors That Cause Large Elevations in Cellular Cyclic GMP Are C-type Natriuretic Peptides, J. Biol. Chem. 1993; 268:3698-3703.
[cited by applicant]
Chrisman, T.D. et al., “Seminal Plasma Factors That Cause Large Elevations in Cellular Cyclic GMP Are C-type Natriuretic Peptides,” Journal of Biological Chemistry, vol. 268; No. 5; 3698-3703 (1993).
[cited by applicant]
Clayton, K.L. et al., “T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) is recruited to the immune synapse, disrupts stable synapse formation and associates with receptor phosphatases,” J Immunol., vo…
[cited by applicant]
Collard, H.R., et al., Plasma biomarker profiles in acute exacerbation of idiopathic pulmony fibrosis, American Journal of Physiology; Lung Cellular and Molecular Physiology, 2010 299: L3-L7.
[cited by applicant]
Das, B.B. and Solinger, R., “Role of Natriuretic Peptide Family in Cardiovascular Medicine,” Cardiovascular & Hematological Agents in Medicinal Chemistry, vol. 7; 29-42 (2009).
[cited by applicant]
Flick et al., Leukocytes Are Required for Increased Lung Microvascular Permeability after Microembolization in Sheep, Circ. Res. 48:344-351, 1981.
[cited by applicant]
Gao, G.F. and Jakobsen, B.K., “Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor,” Immunology Today, vol. 21; No. 12; 630-636 (2000).
[cited by applicant]
Goaddard, J.C et al., “A computer image analysis system for microvessel density measurement in solid tumours,” Angiogenesis, vol. 5; 15-20 (2002).
[cited by applicant]
Gul et al., Changing Definitions of Sepsis, Turk J Anaesthesiol Reanim. Jun. 2017; 45(3): 129-138.
[cited by applicant]
Hamid, O. et al., “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma,” N Eng J Med., vol. 369; No. 2; 134-144 (2013).
[cited by applicant]
Han, H., et al., Thymic Stromal Lymphopoietin Amplifies the Differentiation of Alternatively Activated Macrophages, Journal of Immunology, 2013, 190:904-912.
[cited by applicant]
Harbeck RJ, Immunophenotyping of Bronchoalveolar Lavage Lymphocytes, Clin Diagn Lab Immunol. 1998, 5(3):271-7.
[cited by applicant]
Hasnis, E. et al., “Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy,” Neoplasia, vol. 16; 501-510 (2014).
[cited by applicant]
Heflin A C Jr and Brigham K L., Prevention by granulocyte depletion of increased vascular permeability of sheep lung following endotoxemia, J. Clin. Invest. 68:1253-1260, 1981.
[cited by applicant]
Hendrickson, C.M. and Matthay, M.A., Viral Pathogens and Acute Lung Injury: Investigation Inspired by the SARS Epidemic and the 2009 H1N1 Influenza Pandemic, Semin Respir Grit Care Med, vol. 34; 475-486 (2013).
[cited by applicant]
Hunt, P.J. et al., “Bioactivity and Metabolism of C-Type Natriuretic Peptide in Normal Man,” Journal of Clinical Endocrinology and Metabolism, vol. 78; No. 6; 1428-1435 (1994).
[cited by applicant]
Igaki et al., Effects of Intravenously Administered C-type Natriuretic Peptide in Humans: Comparison with Atrial Natriuretic Peptide, Hypertens Res 1998; 21: 7-13.
[cited by applicant]
Imura, H. et al., “The Natriuretic Peptide System in the Brain: Implication in the Central Control of Cardiovascular and Neuroendocrine Functions,” Frontiers in Neuroendocrinology, vol. 13; No. 3; 217-249 (1992).
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/037031, mailed on Jan. 31, 2022, 19 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/037061, mailed on Dec. 8, 2021, 17 pages.
[cited by applicant]
Ise, W. et al., “T Follicular Helper Cell-Germinal Center B Cell Interaction Strength Regulates Entry into Plasma Cell or Recycling Germinal Center Cell Fate,” Immunity, vol. 48; 702-715 (2018).
[cited by applicant]
Itoh, H. and Nakao, K., “Natriuretic peptide system,” Nihon Rinsho., vol. 55; 1923-1936 (1997). (English Abstract Attached).
[cited by applicant]
Kimura, T. et al., “C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice,” Respiratory Research, vol. 17; No. 19; 17 pages (2016).
[cited by applicant]
Kimura, T. et al., “C-type natriuretic peptide attenuates lipopolysaccharide-induced acute lung injury in mice,” Journal of Surgical Research, vol. 194; 631-637 (2015).
[cited by applicant]
Koller, K.J. et al., “Selective Activation of the B Natriuretic Peptide Receptor by C-Type Natriuretic Peptide,” Science, vol. 252; 120-123 (1991).
[cited by applicant]
Li, W. et al., “Monitoring of tumor vascular normalization: the key points from basic research to clinical application,” Cancer Management and Research, vol. 10; 4163-4172 (2018).
[cited by applicant]
Li, Y-T., et al., Monocyte Chemoattractant Protein-1, a Possible Biomarker of Multiorgan Failure and Mortality in Ventilator-Associated Pneumonia, International Journal of Molecular Sciences, 2019:20 (9): 2218.
[cited by applicant]
Lumsden, N.G. et al., “C-Type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target,” Curr Pharm Des., vol. 16; No. 37; 4080-4088 (2010).
[cited by applicant]
Malyszko et al., Kozlowska K, Kozlowski L, Malyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant 2017; 32: 924-36.
[cited by applicant]
Matsumoto et.al., An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis, Int J Exp Pathol. Apr. 2013; 94(2):93-103.
[cited by applicant]
Mellman, I. et al., “Cancer immunotherapy comes of age,” Nature, vol. 480; No. 7378; 480-489 (2011).
[cited by applicant]
Miller et al., Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010; 2: 2490-518.
[cited by applicant]
Mkrtichyan, M. et al., “B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets,” Journal of Immunol., vol. 189; No. 5; 2338-2347 (2012).
[cited by applicant]
Nagase, M. et al., “Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats,” Journal of Hypertension, vol. 15; 1235-1243 (1997).
[cited by applicant]
Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2021/037061; mailed Dec. 22, 2022.
[cited by applicant]
Nuglozeh, E. and Kozak, L.P., “Genetic mapping of the C-type natriuretic peptide receptor (Npr2) gene to mouse Chromosome 4,” Mammalian Genome, vol. 8; 624-625 (1997).
[cited by applicant]
O hAinmhire, E. and Humphreys, B.D., “Fibrotic Changes Mediating Acute Kidney Injury to Chronic Kidney Disease Transition,” Nephron, vol. 137; 264-267 (2017).
[cited by applicant]
Ogawa, Y. et al., “Molecular Cloning and Chromosomal Assignment of the Mouse C-Type Natriuretic Peptide (CNP) Gene (Nppc): Comparison with the Human CNP Gene (NPPC),” Genomics, vol. 24; 383-387 (1994).
[cited by applicant]
Ogawa, Y. et al., “Molecular Cloning of the Complementary DNA and Gene That Encode Mouse Brain Natriuretic Peptide and Generation of Transgenic Mice That Overexpress the Brain Natriuretic Peptide Gene,” J Clin. Invest.,…
[cited by applicant]
Pardoll, D.M., “The blockade of immune checkpoints in cancer immunotherapy,” Nat Rev Cancer, vol. 12; No. 4; 252-264 (2012).
[cited by applicant]
Park, J. et al., “Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment,” Cancerl Cell, vol. 30; 953-967 (2016).
[cited by applicant]
Peng, Y. et al., “Critical roles of miRNA-mediated regulation of TGFb signalling during mouse cardiogenesis,” Cardiovascular Research, vol. 103; No. 2; 258-267 (2014).
[cited by applicant]
Perazella M.A., Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012; 7: 1713-21.
[cited by applicant]
Potter, L.R. and Hunter, T., “Guanylyl Cyclase-linked Natriuretic Peptide Receptors: Structure and Regulation,” The Journal of Biological Chemistry, vol. 276; No. 9; 6057-6060 (2001).
[cited by applicant]
Potter, L.R., “Natriuretic Peptide Metabolism, Clearance and Degradation,” FEBS J., vol. 278; No. 11; 1808-1817 (2011).
[cited by applicant]
Ribas, A. et al., “Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma,” Journal of Clinical Oncology, vol. 31; No. 5; 7 Pages (2013).
[cited by applicant]
Rosenblatt, J. et al., “PD-1 blockade by CT-011, anti PD-1 antibody, enhances ex-vivo T cell responses to autologous dendritic/myeloma fusion vaccine,” J Immunother., vol. 34; No. 5; 409-418 (2011).
[cited by applicant]
Schulz, S. et al., “The Primary Structure of a Plasma Membrane Guanylate Cyclase Demonstrates Diversity within This New Receptor Family,” Cell, vol. 58; 1155-1162 (1989).
[cited by applicant]
Schupp, J.C., et al., Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis, PLoS One, 2015 10(1): e0116775.
[cited by applicant]
Sheth et al., Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection, Frontiers in Cellular Neuroscience, Oct. 27, vol. 11, 2017.
[cited by applicant]
Singer et al., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA 2016; 315(8): 801-810.
[cited by applicant]
Sudoh, T. et al., “Cloning nd Sequence Analysis of cDNA Encoding a Precursor for Human Brain Natriuretic Peptide,” Biochemical and Biophysical Research Communications, vol. 159; No. 3; 1427-1434 (1989).
[cited by applicant]
Suga, S. et al., “Receptor Selectivity of Natriuretic Peptide Family, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and C-Type Natriuretic Peptide,” Endocrinology, vol. 130; No. 1; 229-239 (1992).
[cited by applicant]
Suga, S. et al., “Regulation of Endothelial Production of C-Type Natriuretic Peptide by Interaction between Endothelial Cells and Macrophages,” Endocrinology, vol. 139; No. 4; 1920-1926 (1998).
[cited by applicant]
Tang, M., et al., TNF-a Mediated Increase of HIF-1a Inhibits VASP Expression, Which Reduces Alveolar-Capillary Barrier Function during Acute Lung Injury (ALI), PLoS One, Jul. 22, 2014;9(7):e102967.
[cited by applicant]
Topalian, S.L. et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” The New England Journal of Medicine, vol. 366; No. 26; 43-54 (2012).
[cited by applicant]
Vesely, B.A. et al., “Five cardiac hormones decrease the number of human small-cell lung cancer cells,” European Journal of Clinical Investigation, vol. 35; 388-398 (2005).
[cited by applicant]
Vesely, B.A. et al., “Four peptide hormones decrease the number of human breast adenocarcinoma cells,” European Journal of Clinical Investigation, vol. 35; 60-69 (2005).
[cited by applicant]
Vesely, D.L., “Metabolic Targets of Cardiac Hormones' Therapeutic Anti-Cancer Effects,” Current Pharmaceutical Design, vol. 16; 1159-1166 (2010).
[cited by applicant]
Wendt, D.J. et al., “Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3-Related Dwarfism,” The Journal of Pharma…
[cited by applicant]
Wisniewski, K. et al., “New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists,” Journal of Medicinal Chemistry, vol. 54; 4388-4398 (2011).
[cited by applicant]
Wu, K. et al., “Structural Basis of a Flavivirus Recognized by Its Neutralizing Antibody,” The Journal of Biological Chemistry, vol. 278; No. 46; 46007-46013 (2003).
[cited by applicant]
Yu et al., Current Strategies to Combat Cisplatin-Induced Ototoxicity Front. Pharmacol., Jul. 3, 2020; 12 pages.
[cited by applicant]
Zenitani, M. et al., “C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells,” Cancer Medicine, vol. 5; No. 5; 795-805 (2016).
[cited by applicant]
Zhao, Y. et al., “Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma,” PNAS, vol. 116; No. 6; 2210-2219 (2019).
[cited by applicant]
Bogdanov et al., “Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs”, Theranostics, vol. 2, No. 6, Jun. 4, 2012, pp. 553-576.
[cited by applicant]
Breinholt et al. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with FGF Receptor 3-Relate…
[cited by applicant]
Forsberg et al. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Res. Mar. 1, 2019; 79(5):899-904 (Year: 2019).
[cited by applicant]
Khair et al. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Front Immunol. Mar. 19, 2019; 10:453 (Year: 2019).
[cited by applicant]
Kimura et al., “C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice”, Respiratory Research, vol. 17, No. 19, 2016, 17 pages.
[cited by applicant]
Murakami et al., “C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice”, American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 287, No. 6, 2004, pp. L1172-L1177.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 18/009,596, mailed on Nov. 21, 2025, 33 pages.
[cited by applicant]